Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002113 · ClinicalTrials.gov registry record · NA

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

A NA study, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
64
Enrollment target

NCT00002113 is a NA study that has completed, run by Pfizer. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002113, a NA study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target

Study Summary

To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS. Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not been associated with hematologic suppression and does not produce renal impairment that can result in higher serum flucytosine levels, this combination may be better tolerated than is amphotericin B plus flucytosine.

Interventions

  • DRUG Fluconazole
  • DRUG Flucytosine

Trial Details

FieldValue
Enrollment Target 64 participants
Phase NA

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00002113

The ClinicalTrials.gov registry entry for NCT00002113 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.

NCT00002113 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002113 about?

NCT00002113 is a clinical study titled "A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.". To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS. Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not been associated with hematologic suppre...

What is the current status of trial NCT00002113?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants.

What interventions are being tested in trial NCT00002113?

The interventions under investigation include: Fluconazole (DRUG), Flucytosine (DRUG).

Who is sponsoring clinical trial NCT00002113?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.